* RenovoRx Inc reported a quarterly adjusted loss of 10 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of three analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -11 cents to -9 cents per share.
* Reported revenue was zero; analysts expected zero.
* RenovoRx Inc's reported EPS for the quarter was a loss of 10 cents.
* The company reported a quarterly loss of $2.39 million.
* RenovoRx Inc shares had fallen by 0.9% this quarter and lost 51.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 11.1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for RenovoRx Inc is $5.50 This summary was machine generated from LSEG data August 15 at 02:26 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.10 -0.10 Met
Mar. 31 2024 -0.14 -0.07 Beat
Dec. 31 2023 -0.30 -0.31 Missed
Sep. 30 2023 -0.30 -0.13 Beat
Comments